Key points from this note:
• We recommend accumulating the stock as it bounced back on strong volume after testing its pivot price level. We are up 26% on the name since adding it in May 2021.
• Rebound of sales in the U.S. and Europe, along with the successful rollout of ELEMIS in China, continues to be the key growth driver.
• The stock found strong support at its pivot price level after breaking out of a stage-three consolidation. We can expect strong momentum going forward as the Hong Kong market has witnessed two follow-through days in the last five trading sessions.
• Consensus expects double-digit revenue and EPS growth until FY23. Institutional sponsorship has steadily increased in the last few quarters